Oracle releases AI Database 26ai with built-in artificial intelligence
SAN FRANCISCO - Counterpart Health, Inc., a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV), announced Monday the appointment of two executives to support the expansion of its AI-powered physician enablement platform. The move comes as Clover Health, with a market capitalization of $1.35 billion and annual revenue of $1.6 billion, shows strong revenue growth of 22% year-over-year.
Blaine Lindsey joins as Vice President of Enterprise Growth and Partnerships, while Shannon Jacobs takes the role of President of Market Operations for the Gulf Region, according to a company press release.
The appointments come as the company seeks to scale adoption of Counterpart Assistant, its AI platform designed to help physicians identify high-risk patients and manage chronic conditions earlier, particularly in underserved areas.
Lindsey, who previously held leadership positions at Aledade, Honest Health, and AnsibleHealth, will focus on developing partnerships with risk-bearing organizations to expand the platform’s reach.
Jacobs, formerly President of the Gulf Region at Main Street Health, will lead expansion efforts and optimize performance of Counterpart’s physician network in the Gulf Region.
"Counterpart Assistant was built to serve the full spectrum of physician practices," said Conrad Wai, CEO of Counterpart Health in the statement. "Whether we’re partnering with large health systems, national plans, regional payviders, or independent practices in rural communities, we’ve identified that the need is the same: actionable intelligence that improves care without overwhelming providers."
Counterpart Health originated as Clover Assistant within Clover Health before expanding its AI platform beyond Clover’s Medicare Advantage plan to reach more healthcare providers nationwide.
In other recent news, Clover Health Investments Corp reported its second-quarter 2025 earnings, revealing a revenue of $477.62 million. This figure surpassed the forecasted $468.3 million, resulting in a 1.99% surprise for investors. Despite the revenue beat, the stock experienced a slight decline in value following the announcement. The stock closed at $2.88, showing a decrease of 1.04%, before rising slightly by 0.69% to $2.9 in after-hours trading. These developments highlight the company’s ability to exceed revenue expectations, even as the stock’s performance showed mixed reactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.